Anti-Inflammatory Properties of Chemical Probes in Human Whole Blood: Focus on Prostaglandin E2 Production

Filip Bergqvist1,2*, Yvonne Sundström1,2, Ming-Mei Shang1,2, Iva Gunnarsson1, Ingrid E. Lundberg1, Michael Sundström1,2, Per-Johan Jakobsson1,2 and Louise Berg1,2*

1 Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet, and Karolinska University Hospital, Stockholm, Sweden, 2 The Structural Genomic Consortium (SGC), Karolinska Institutet, Stockholm, Sweden

We screened 57 chemical probes, high-quality tool compounds, and relevant clinically used drugs to investigate their effect on pro-inflammatory prostaglandin E2 (PGE2) production and interleukin-8 (IL-8) secretion in human whole blood. Freshly drawn blood from healthy volunteers and patients with systemic lupus erythematosus (SLE) or dermatomyositis was incubated with compounds at 0.1 or 1 µM and treated with lipopolysaccharide (LPS, 10 µg/ml) to induce a pro-inflammatory condition. Plasma was collected after 24 h for lipid profiling using liquid chromatography tandem mass spectrometry (LC-MS/MS) and IL-8 quantification using enzyme-linked immunosorbent assay (ELISA). Each compound was tested in at least four donors at one concentration based on prior knowledge of binding affinities and in vitro activity. Our screening suggested that PD0325901 (MEK-1/2 inhibitor), trametinib (MEK-1/2 inhibitor), and selumetinib (MEK-1 inhibitor) decreased while tofacitinib (JAK inhibitor) increased PGE2 production. These findings were validated by concentration-response experiment in two donors. Moreover, the tested MEK inhibitors decreased thromboxane B2 (TXB2) production and IL-8 secretion. We also investigated the lysophosphatidylcholine (LPC) profile in plasma from treated whole blood as these lipids are potentially important mediators in inflammation, and we did not observe any changes in LPC profiles. Collectively, we deployed a semi-high throughput and robust methodology to investigate anti-inflammatory properties of new chemical probes.

Keywords: prostaglandin E2, whole blood assay, interleukin-8, inflammation, drug screen

HIGHLIGHTS

- Inhibitors for MEK decreased PGE2 and TXB2 production
- Inhibitors for MEK and ERK decreased IL-8 secretion
- JAK inhibitor tofacitinib increased PGE2 and TXB2 production
INTRODUCTION

Inflammation is a highly controlled immune response to eliminate the cause of tissue injury or infection and to initiate tissue repair back to homeostasis via resolution (Nathan, 2002; Buckley et al., 2013). However, inflammation is not always terminated. Unresolved inflammation causes persistent pain, tissue degeneration, and loss of function. In particular, inflammatory responses drive many autoimmune diseases (McInnes and Schett, 2011) and inflammation is a hallmark of cancer (Hanahan and Weinberg, 2011). Thus, there is a great need for new therapies that are anti-inflammatory and safe.

Prostaglandin E₂ (PGE₂) is a potent lipid mediator of inflammation and immune responses, and PGE₂ is a central mediator of pain, edema, and cartilage erosion typically observed in the joints of rheumatoid arthritis patients (Akaogi et al., 2012; Fattahi and Mirshafiey, 2012). In addition, PGE₂ is a promotor of the immunosuppressive tumor microenvironment with major impact on tumor progression (Wang and Dubois, 2010; Hanahan and Weinberg, 2011; Ricciotti and Fitzgerald, 2011). During inflammation, PGE₂ is synthesized via conversion of arachidonic acid by cyclooxygenases (COX-1 and COX-2) into unstable PGH₂ that is further metabolized by the inducible terminal synthase microsomal prostaglandin E synthase-1 (mPGES-1) to generate PGE₂. Multiple non-steroidal anti-inflammatory drugs (NSAIDs) exist in clinical practice that unselectively decrease PGE₂ production via inhibition of COX, but these drugs are all associated with adverse effects. Hence, selective inhibition of PGE₂ production with small molecule inhibitors could therefore be a desirable therapeutic strategy in inflammation and cancer (Bergqvist et al., 2020).

Interleukin-8 (IL-8) is a potent chemoattractant and activator of neutrophils. IL-8 signaling is implicated in multiple chronic inflammatory diseases (Russo et al., 2014) and cancer (Waugh and Wilson, 2008). For example, a recent meta-analysis concluded that patients suffering from systemic lupus erythematosus (SLE) have increased levels of circulating IL-8 (Mao et al., 2018). Patients with central neuropsychiatric SLE have increased concentration of IL-8 in cerebrospinal fluid compared to patients with non-central neuropsychiatric SLE (Yoshio et al., 2016). IL-8 is also associated with renal damage and pulmonary fibrosis in SLE patients (Lit et al., 2006; Nielepkowicz-Goździańska et al., 2014). Given that IL-8 is a stimulant for neutrophil activation, which plays a significant role in the pathogenesis of SLE (Kaplan, 2011), targeting IL-8 secretion or signaling could constitute a therapeutic strategy for SLE. A similar role of neutrophils and net formation has been reported in patients with dermatomyositis (DM) (Zhang et al., 2014; Peng et al., 2018). In cancer, IL-8 is highly expressed in several types of cancer tissues (David et al., 2016) and serum concentration of IL-8 correlates with tumor burden (Alfaro et al., 2017). The tumor-favoring actions of IL-8 include promotion of angiogenesis, increased survival of cancer stem cells, and attraction of myeloid cells that indorse the immunosuppressive tumor microenvironment (Alfaro et al., 2017).

In this study, we aimed to evaluate the effect of 57 chemical probes, high-quality tool compounds, and relevant control drugs on eicosanoid production and IL-8 secretion in human whole blood. A chemical probe is defined as “… a selective small-molecule modulator of a protein’s function that allows the user to ask mechanistic and phenotypic questions about its molecular target in biochemical, cell-based or animal studies” (Arrowsmith et al., 2015), and these compounds follow the criteria of in vitro potency (IC₅₀ or Kd <100 nM), high selectivity versus other protein subfamilies (>30-fold), and on-target cell activity at 1 μM. The chemical probes and other high-quality tool compounds included are mainly epigenetic modulators and kinase inhibitors that were produced in academic collaborations or donated by pharmaceutical companies within the Structural Genomic Consortium (SGC, www.thesgc.org), which aims to investigate novel targets for drug development in open science and in collaboration with the pharmaceutical industry. These inhibitors were tested here at one concentration (in triplicates, n = 4–15 donors) based on previous knowledge of binding affinities and toxicity in vitro, as assessed using other validated assays in our laboratories (https://ultra-dd.org/tissue-platforms/cell-assay-datasets).

MATERIALS AND METHODS

Ethical Approval and Consent to Participate

Ethical approval for this study was granted by local research ethics committee at Karolinska University hospital (Dnr 02-196) and the Regional Ethical Review Board in Stockholm (Dnr 2015/2001-31/2). Full informed consent according to the Declaration of Helsinki was obtained from all patients.

Collection of Blood

Peripheral venous blood was drawn from 10 females and 6 males, aged between 27 and 81 years. Healthy controls (n = 4) and two patient groups were included: SLE (n = 9) and DM (n = 3). Patients with diagnosis SLE or DM and aged 18 or older were recruited from the Rheumatology Clinic at Karolinska University Hospital. Patients with ongoing treatment including Sendoxan (cyclophosphamide) and Benlysta (belimumab) or with kidney failure as defined by present dialysis or previous kidney transplantation were excluded. Disease activity measurements were not obtained at the time of sampling. For healthy control and patients characteristics, see Supplementary Table 1. The blood was collected in tubes containing sodium heparin (1000 U/ml).

Inhibitors

The inhibitors (chemical probes and other high-quality tool compounds) tested here were obtained through the SGC (www.thesgc.org) and supplied by different distributors (Supplementary Table 2). Inhibitors and control drugs (Supplementary Table 2) were reconstituted at 10 mM in DMSO (D2250, Sigma-Aldrich), aliquoted in Eppendorf tubes and patients characteristics, see Supplementary Table 1. The blood was collected in tubes containing sodium heparin (1000 U/ml).
as positive control for inhibition of prostanoid production. Lipopolysaccharide (LPS; L6529, Sigma-Aldrich) was reconstituted in phosphate-buffered saline (PBS) (D8537, Sigma-Aldrich) to a final concentration of 0.1 mg/ml and kept at +8°C.

**Whole Blood Assay**

Inhibitors and vehicle control (DMSO) were diluted in PBS at room temperature with no direct light on. The treatments were prepared in 25 µl portions to U-shaped 96-well plate and 200 µl of freshly drawn heparin blood (< 2 h at room temperature) was added to the plate. The plate was incubated at 37°C for 30 min and then 25 µl of 0.1 mg/ml LPS in PBS was added followed by pipetting up and down 3 times (final concentration of LPS was 10 µg/ml). The tested concentration for inhibitor was 0.1 or 1 µM (Supplementary Table 1). The plate was incubated for 24 h at 37°C and then centrifuged at 3000 g for 10 min at 4°C. Working on ice, 100 µl plasma was recovered to a new plate (for prostanoid profiling) and from this 20 µl was transferred to a second plate (for IL-8 quantification). The plates were sealed with aluminum foil and stored at -80°C.

**Extraction of Lipids**

Plasma samples (80–240 µl) were thawed on ice and spiked with 50 µl deuterated internal standard mix containing 17 ng 6-keto-PGF1α-d4, 8 ng PGF2α-d4, 12 ng PGE2-d4, 8 ng PGD2-d4, 8 ng thromboxane B2 (TXB2)-d4, and 8 ng 15-deoxy-A12,14PGJ2-d4 (Cayman Chemical Company) prepared in 100% methanol. Protein precipitation was performed by addition of 800 µl 100% methanol, followed by vortexing, and centrifugation at 3000 g for 10 min at 4°C. The supernatants were collected in a new plate and evaporated under vacuum for 4 h. The evaporated samples (100–200 µl) were diluted to 1 ml with 0.05% formic acid in water and then loaded onto Oasis HLB 1 cc 30 mg plate (Waters Corporation, USA) that had been pre-conditioned with 1 ml of 100% methanol and 1 ml of 0.05% formic acid in water. The plate was washed with 10% methanol, 0.05% formic acid in water and lipids were eluted with 100% methanol. The eluates were dried under vacuum overnight and stored at -20°C until reconstituted in 50 µl of 20% acetonitrile in water prior to analysis with liquid chromatography tandem mass spectrometry (LC-MS/MS).

**Lipid Profiling by LC-MS/MS**

Lipids were quantified in negative mode with multiple reaction monitoring method, using a triple quadrupole mass spectrometer (Acquity TQ detector, Waters) equipped with an Acquity H-class UPLC (Waters). Eicosanoid were purchased from Cayman Chemicals and individually optimized for based on precursor ion m/z, cone voltage, collision energy, and fragment ion m/z (Supplementary Table 3). An eicosanoid mix containing all standards of interest was used to check interference in the LC-MS/MS analysis. Lysophosphatidylcholine (LPC)(14:0) and LPC (18:0) were used to set optimal analytical parameters for quantification of LPCs. Separation of lipids was performed on a 50 x 2.1-mm Acquity UPLC BEH C18 column 1.7 µm (Waters) with a 12-min stepwise linear gradient (20%–95%) at a flowrate of 0.6 ml/min with 0.05% formic acid in acetonitrile as mobile phase B and 0.05% formic acid in water as mobile phase A. Data were analyzed using MassLynx software, version 4.1, with internal standard calibration and quantification to external standard curves for prostanoids. LPCs were normalized as area-% within each injection. Only lipids with peaks intensities of signal-to-noise greater than 10 (S/N >10) were considered in our data analysis.

**Development of Whole Blood Assay**

The whole blood assay was developed to screen for changes in multiple eicosanoids. Each eicosanoid and corresponding deuterated variant were individually optimized in the LC-MS/MS analysis. A dilution curve containing 6-keto PGF1α-d4, PGE2-d4, PGD2-d4, PGF2α-d4, TXB2-d4, 15d-PGJ2-d4, LTBr-d4, LTC4-d5, LTD4-d5, 5-HETE-d8, 12-HETE-d8, 15-HETE-d8, and undeuterated variants of 13-HODE, RvD1, RvD2, 17-hydroxy DHA, and protectin DX was spiked into 100 µl plasma at different stages throughout the extraction. A dilution curve was spiked in water at the same step. The dilution curve ranged from 0.006 to 1.5 pmol as final amount injected on the column in the LC-MS/MS analysis. This enabled us to investigate the lower limit of quantification (LLOQ), recovery efficacy, and matrix effect for each eicosanoid. The LLOQ injected on column was considered as great (0.02–0.05 pmol), good (0.1–0.2 pmol), or poor (0.4–1.5 pmol). Eicosanoids with great LLOQ were PGE2, PGF2α, TXB2, RvD1, RvD2, LTBr, protectin DX, and 13-HODE; good LLOQ were 6-keto PGF1α, PGD2, 5-HETE, 15-HETE, and LTD4; poor LLOQ were 15d-PGJ2, 12-HETE, 17-hydroxy DHA, and LTC4. The extraction recovery rates were 33%–125%. The response in plasma compared to 20% acetonitrile were 52%–116% due to matrix effects. The estimated LLOQ in 100 µl plasma was approximately 1 ng/ml for the best performing eicosanoids including PGE2, TXB2, PGF2α, RvD1, RvD2, and protectin DX. We can conclude that the method provided similar quantitative performance in plasma for many eicosanoids.

LPS at 10 µg/ml induced PGE2 and TXB2 production in human whole blood, which are the two dominant eicosanoids produced under these conditions (Mazaleuskaya et al., 2016). All other eicosanoids were below the LLOQ. We chose 10 µg/ml of LPS based on the consensus in the literature for this type of assay, yielding a robust amount of PGE2 (49 ± 4 ng/ml, n = 5 donors) and TXB2 (24 ± 9 ng/ml, n = 5 donors). The prostanoid production was completely blocked using the dual COX-1/2 inhibitor diclofenac (10 µM). High concentration of DMSO (0.1%) slightly decreased PGE2 production by 20% (n = 2 donors) while DMSO at 0.01% or 0.001% had no effect. The intra-assay coefficient of variation (CV, n = 20 technical replicates) was 12% and 11% for PGE2 and TXB2, respectively. The inter-assay CV for control material (n = 3 donors) was 20% for PGE2 and 30% for TXB2. This was performed on blood that was drawn, incubated, extracted, and analyzed at separate occasions. The suppression in signal due to matrix effects and/or recovery efficiency varied between donors and experiments, ranging from 10% to 70% suppression compared to signal in extracted blank (mean ± SD, n = 6 donors, PGE2: 45% ± 25%,
TXB$_2$: 40 ± 20%). In summary, 24-h incubation of whole blood with 10 µg/ml LPS resulted in profound induction of the COX-1/2 products PGE$_2$ and TXB$_2$ that was efficiently blocked by diclofenac at 10 µM.

**Quantification of IL-8**

IL-8 was quantified in plasma by human IL-8 (CXCL8) enzyme-linked immunosorbent assay (ELISA) development kit (3560-1H, Mabtech) according to manufacturer’s instructions.

**Statistical Analyses**

Data are presented as mean ± SEM if not stated otherwise. Statistical analyses were performed using GraphPad Prism 6 (GraphPad Software). One-sample t-test and two-sample t-test with Bonferroni correction were used to test significant difference. Statistical significance level was set to p < 0.05.

**RESULTS**

**Effect on PGE$_2$ and TXB$_2$ Production**

Our screening of inhibitors suggested that selected kinase inhibitors affected prostanoid production (Figure 1). The strongest reduction in PGE$_2$ production was observed by MEK-1 inhibitor PD0325901 (31% ± 6%, p = 0.001, n = 4) and MEK-1/2 inhibitor trametinib (34% ± 7%, p < 0.0001, n = 15). Moderate suppression in PGE$_2$ concentration was found for MEK-1/2 inhibitor selumetinib (65% ± 9%, p = 0.02, n = 5), ERK-1/2 inhibitor SCH772984 (76% ± 11%, p = 0.04, n = 13), and p38 inhibitor skepinone-L (76% ± 8%, p = 0.01, n = 13). However, the tested p38 inhibitor pamapimod did not affect PGE$_2$ production. Two of these compounds decreased TXB$_2$ production, namely trametinib (63% ± 6%, p = 0.02, n = 15) and selumetinib (74% ± 7%, p = 0.02, n = 5). Diclofenac, here used as a positive control for inhibition of prostanoid production, blocked the prostanoid production while selective COX-2 inhibitor NS-398 inhibited only PGE$_2$ production, in agreement with previously reported data for these compounds in whole blood assay (Larsson et al., 2019). The JAK inhibitor tofacitinib increased both PGE$_2$ (286% ± 51%, p = 0.01, n = 6) and TXB$_2$ (169% ± 20%, p = 0.02, n = 6) production. The IRAK-1/4 inhibitor I slightly increased the concentrations of PGE$_2$ (139% ± 15%, p = 0.04, n = 7) and TXB$_2$ (133% ± 8%, p = 0.008, n = 7).

We chose to investigate the strongest observed effects in more detail by performing concentration–response experiments for PD0325901, trametinib, selumetinib, and tofacitinib. All three MEK inhibitors showed a concentration-dependent response on both PGE$_2$ and TXB$_2$ production while tofacitinib showed a concentration-dependent response on PGE$_2$ production (Figure 2).

**Effect on IL-8 Secretion**

In line with the effect on prostanoid production, reduction in IL-8 secretion was found for PD0325901 (24% ± 9%, p = 0.03, n = 3), trametinib (27% ± 5%, p < 0.0001, n = 13), and selumetinib (45% ± 10%, p = 0.03, n = 3) (Figure 3). Moderate reduction in IL-8 secretion was found for SCH772984 (62% ± 9%, p = 0.002, n = 12) and diclofenac (66% ± 8%, p = 0.003, n = 11). We could also observe that tofacitinib increased IL-8 secretion (225% ± 57%, p = 0.16, n = 3), however not with statistical significance.

**Effect on LPC Profile**

We measured LPC species within our targeted LC-MS/MS analysis. LPCs are mainly generated by metabolism of membrane phosphatidylcholine by cytosolic phospholipase A$_2$ (Burke and Dennis, 2009). These lipids have been reported to be involved in several cellular processes; sometimes with opposing effect depending on degree of saturation, concentration, and biological context (Sevastou et al., 2013; Drzazga et al., 2014). We observed no difference in total LPC or LPC profile when whole blood was treated with LPS neither did any of the tested inhibitors alter the LPC profile (Figure 4).
inhibitors with known target specificities and IL-8 secretion in human whole blood for 57 high-quality donors. Statistical significance was tested using two-sample t-test based on fold-change (< 0.5 or >2) and p-value (< 0.05) are highlighted. Each inhibitor was tested in 3–13 donors. Statistical significance was tested using one sample t-test (p < 0.05). IL-8, interleukin-8.

**FIGURE 3** Volcano plot showing effects on IL-8 secretion in LPS-induced human whole blood. The top altered conditions compared to vehicle control based on fold-change (< 0.5 or >2) and p-value (< 0.05) are highlighted. Each inhibitor was tested in 3–13 donors. Statistical significance was tested using one sample t-test (p < 0.05). IL-8, interleukin-8.

**DISCUSSION**

We have tested the inhibitory effect on prostanoid production and IL-8 secretion in human whole blood for 57 high-quality inhibitors with known target specificities and *in vitro* potencies. None of the tested epigenetic modulators, which are acting on demethylases, bromodomains, or methyltransferases, affected PGE$_2$ or IL-8 concentration. Inhibition of MEK-1/2 or ERK decreased PGE$_2$ production and IL-8 secretion in this assay. This effect was observed for allosteric inhibitor trametinib (MEK-1/2), non-ATP-competitive inhibitors PD0325901 (MEK-1) and selumetinib (MEK-1/2), and ATP-competitive inhibitor SCH772984 (ERK-1/2). These kinase targets are part of the RAS/RAF/MEK/ERK signaling transduction pathway, where inhibition of MEK prevents the downstream phosphorylation and activation of ERK that ultimately regulates cellular responses such as survival, lipid metabolism, and protein translation (McCubrey et al., 2007). For example, MEK-1/2 inhibitor PD184352 decreased PGE$_2$ production in melanoma cell line by decreased COX-2 expression due to inhibition of phosphorylation on ERK (Zelenay et al., 2015) and trametinib reduced IL-8 production in melanoma cell line (Hartman et al., 2017). We found that our positive control diclofenac for blocking prostanoid production decreased IL-8 secretion, which is explained by the fact that PGE$_2$ stimulates IL-8 production in cultured cells (Agro et al., 1996; Caristi et al., 2005; Aso et al., 2012; Venza et al., 2012). While our study mainly focused on identifying inhibitory effects, we observed that JAK inhibitor tofacitinib increased both PGE$_2$ production and IL-8 secretion. Tofacitinib is used to treat rheumatoid arthritis and it is known that tofacitinib can increase the expression of pro-inflammatory mediators, including PGE$_2$, in macrophages by acting inhibitory on the expression of anti-inflammatory IL-10 (Kothari et al., 2014). The increased formation of pro-inflammatory PGE$_2$ and platelet activating thromboxane A$_2$ (as measured by stable metabolite TXB$_2$) in human whole blood may be associated with the recently recognized increased risk of thromboembolism associated with JAK inhibitors in treatment of rheumatoid arthritis (Scott et al., 2018). Moreover, we did not observe any changes in LPC profile by LPS alone or the tested compounds. While LPCs can be generated by degradation of phosphatidylycerol, LPCs are continuously incorporated back into the plasma membrane (Law et al., 2019). This would result in no net change in LPCs while other phospholipid species may change in abundance. We acknowledge that the limitation of our study is the usage of one concentration per tested inhibitor.
However, the used concentrations were based on reported IC\textsubscript{50} and/or EC\textsubscript{50} values as well as solid experiences in our laboratories using other validated assay systems (https://ultra-dd.org/index.php/tissue-platforms/cell-assay-datasets). The concentrations were selected to avoid cellular toxicity but we acknowledge that greater concentrations might be of relevance considering the bioavailability in blood. Indeed, we demonstrated in concentration–response experiments that greater inhibitory effect could be achieved by increasing the concentration for the MEK inhibitors. However, this increases the risk of off-target effects and/or introduction of cellular toxicity that needs to be taken into account in experimental design and interpretation of results. In conclusion, we identified inhibitors for MEK or ERK as anti-inflammatory hits in our human whole blood assay. Based on the suppression in PGE\textsubscript{2} production and IL-8 secretion, further investigation of the MEK/ERK signaling pathway may inform future therapeutic strategies to treat inflammatory diseases such as SLE and DM.

**DATA AVAILABILITY STATEMENT**

The datasets generated for this study are available on request to the corresponding authors.

**ETHICS STATEMENT**

The studies involving human participants were reviewed and approved by Karolinska University hospital (Dnr 02-196) and the Regional Ethical Review Board in Stockholm (Dnr 2015/2001-31/2). The patients/participants provided their written informed consent to participate in this study.

**AUTHOR CONTRIBUTIONS**

FB, YS, MS, P-JJ, and LB contributed to study conception and design. FB, YS, and M-MS performed experiments. FB analyzed
data, performed statistical analysis, and drafted the manuscript. IG and IL facilitated administrative, technical, or material support. All authors critically revised and approved the final version of the manuscript.

ACKNOWLEDGMENTS

This work was supported by grants from Innovative Medicines Initiative (EU/EFPIA, ULTRA-DD, grant no. 115766), the Swedish Research Council (grant no. 2017-02577), Stockholm County Council (ALF, grant no. 20160378), The Swedish Rheumatism Association (grant no. R-755861), King Gustaf V’s 80 Years Foundation (grant no. n/a), and funds from Karolinska Institutet (grant no. n/a). This manuscript has been released as a preprint at https://doi.org/10.1101/2019.12.30.890715, (Bergqvist et al., 2019).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2020.00613/full#supplementary-material

REFERENCES

Agro, A., Langdon, C., Smith, F., and Richards, C. D. (1996). Prostaglandin E2 enhances interleukin 8 (IL-8) and IL-6 but inhibits GMCSF production by IL-1 stimulated human synovial fibroblasts in vitro. J. Rheumatol 23, 862–868.

Akaogi, J., Nozaki, T., Satoh, M., and Yamada, H. (2012). Role of PGE2 and EP Receptors in the Pathogenesis of Rheumatoid Arthritis and as a Novel Therapeutic Strategy. Endocrine Metab. Immune. Disord. - Drug Targets 6, 383–394. doi: 10.2174/18715300679025711

Alfaro, C., Sanmamed, M. F., Rodriguez-Ruiz, M. E., Teijeira, A., Ohate, C., González, Á., et al. (2017). Interleukin-8 in cancer pathogenesis, treatment and follow-up. Cancer Treat. Rev. 60, 24–31. doi: 10.1016/j.ctrv.2017.08.004

Arrowsmith, C. H., Audia, J. E., Austin, C., Bacll, J., Bennett, J., Blagg, J., et al. (2015). The promise and peril of chemical probes. Nat. Chem. Biol. 11, 536–541. doi: 10.1038/nchembio.1867

Aso, H., Ito, S., Morii, A., Morizuka, M., Suganuma, N., Kondo, M., et al. (2012). Prostaglandin e 2 enhances interleukin-8 production via ep4 receptor in human pulmonary vascular endothelial cells. Am. J. Physiol. - Lung Cell. Mol. Physiol. 302, 266–273. doi: 10.1152/ajplung.00248.2011

Bergqvist, F., Sundström, Y., Shang, M., Gunnarsson, I., Lundberg, I. E., et al. (2012). Biological characterization of new inhibitors of microsomal PGE2 synthase-1 in preclinical models of inflammation and vascular tone. Br. J. Pharmacol. 167, 4625–4638. doi: 10.1111/j.1476-5381.2012.01482x

Law, S. H., Chan, M. L., Marathe, G. K., Parveen, F., Chen, C. H., and Ke, L. Y. (2019). An updated review of lysophosphatidylcholine metabolism in human diseases. Int. J. Mol. Sci. 20. doi: 10.3390/ijms20051149

Løft, M. C. W., Wong, C. K., Tam, L. S., Li, E. K. M., and Lam, C. W. K. (2006). Raised plasma concentration and ex vivo production of inflammatory chemokines in patients with systemic lupus erythematosus. Ann. Rheumatic Dis. 65, 209–215. doi: 10.1136/ard.2005.038315

Mao, Y. H., Zhao, C. N., Liu, L. N., Wu, Q., Dan, Y. L., Wang, D. G., et al. (2018). Increased circulating interleukin-8 levels in systemic lupus erythematosus patients: A meta-analysis. Biomarkers Med. 12, 1291–1302. doi: 10.2217/bmm-2018-0127

Mazaleurskaya, L. L., Lawson, J. A., Li, X., Grant, G., Mesaros, C., Grosser, T., et al. (2016). A broad-spectrum lipidscreen of screening antiinflammatory drug combinations in human blood. ICI Insight 1. doi: 10.1172/ici.insight.87031

McCubrey, J. A., Steelman, L. S., Chappell, W. H., Abrams, S. L., Wong, E. W. T., Chang, F., et al. (2007). Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim. Biophys. Acta - Mol. Cell. Res. 1773, 1263–1284. doi: 10.1016/j.bbamcr.2006.10.001

McInnes, I. B., and Schett, G. (2011). The pathogenesis of rheumatoid arthritis. New Engl. J. Med. 365, 2205–2219. doi: 10.1056/NEJMra1004965

Nathaniel, C. (2002). Points of control in inflammation. Nature 420, 846–852. doi: 10.1038/nature01302

Niełkowicz-Goz, P., Pietras, T., et al. (2014). Exhaled IL-8 in systemic lupus erythematosus with and without pulmonary fibrosis. Archiv Immunologie Ther. Exp. 62, 231–238. doi: 10.1007/s00005-014-0270-5

Peng, Y., Zhang, S., Zhao, Y., Liu, Y., and Yan, B. (2018). Neutrophil extracellular traps may contribute to intestinal lung disease associated with anti-MDA5 autoantibody positive dermatomyositis. Clin. Rheumatol. 37, 107–115. doi: 10.1007/s10067-017-3799-y

Ricciotti, E., and Fitzgerald, G. A. (2011). Prostaglandins and inflammation. Arteriosclerosis Thrombosis Vasc. Biol. 31, 986–1000. doi: 10.1161/ATVBAHA.110.207449

Russo, R. C., Garcia, C. C., Teixeira, M. M., and Amaral, F. A. (2014). The CXCL8/IL-8 chemokine family and its receptors in inflammatory diseases. Archiv Immunologie Ther. Exp. 62, 231–238. doi: 10.1007/s00005-014-0270-5

Scott, I. C., Hider, S. L., and Scott, D. L. (2018). Thromboembolism with Janus Kinase (JAK) Inhibitors for Rheumatoid Arthritis: How Real is the Risk? Drug Safety 41, 645–653. doi: 10.1007/s40264-018-0965-1

Sevastou, I., Kafe, E., Mouratis, M. A., and Aidinis, V. (2013). Lysoglycerophospholipids in chronic inflammatory disorders: The PLA 2/LPC and ATX/LPA axes. Biochim. Biophys. Acta - Mol. Cell. Biol. Lipids 1831, 42–60. doi: 10.1016/j.bbalip.2012.07.019
Venza, L., Visalli, M., Fortunato, C., Ruggeri, M., Ratone, S., Caffo, M., et al. (2012). PGE2 induces interleukin-8 derepression in human astrocytoma through coordinated DNA demethylation and histone hyperacetylation. *Epigenetics* 7, 1315–1330. doi: 10.4161/epi.22446

Wang, D., and Dubois, R. N. (2010). Eicosanoids and cancer. *Nat. Rev. Cancer* 10, 181–193. doi: 10.1038/nrc2809

Waugh, D. J. J., and Wilson, C. (2008). The interleukin-8 pathway in cancer. *Clin. Cancer Res.* 14, 6735–6741. doi: 10.1158/1078-0432.CCR-07-4843

Yoshio, T., Okamoto, H., Kurasawa, K., Dei, Y., Hirohata, S., and Minota, S. (2016). IL-6, IL-8, IP-10, MCP-1 and G-CSF are significantly increased in cerebrospinal fluid but not in sera of patients with central neuropsychiatric lupus erythematosus. *Lupus* 25, 997–1003. doi: 10.1177/0961203316629556

Zelenay, S., Van Der Veen, A. G., Böttcher, J. P., Snelgrove, K. J., Rogers, N., Acton, S. E., et al. (2015). Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity. *Cell* 162, 1257–1270. doi: 10.1016/j.cell.2015.08.015

Zhang, S., Shu, X., Tian, X., Chen, F., Lu, X., and Wang, G. (2014). Enhanced formation and impaired degradation of neutrophil extracellular traps in dermatomyositis and polymyositis: A potential contributor to interstitial lung disease complications. *Clin. Exp. Immunol.* 177, 134–141. doi: 10.1111/cei.12319

**Conflict of Interest:** The SGC receives funds from AbbVie, Bayer Pharma, Boehringer Ingelheim, the Canada Foundation for Innovation, the Eshelman Institute for Innovation, Genome Canada, Janssen, Merck (Darmstadt, Germany), MSD, Novartis Pharma, the Ontario Ministry of Economic Development and Innovation, Pfizer, the Sao Paulo Research Foundation, Takeda and the Wellcome Trust (authors: FB, YS, M-MS, MS, P-JJ, and LB). These funders had no direct role in study conceptualization, design, data collection, analysis, decision to publish, or preparation of the manuscript. P-JJ is member of the board of directors at Gesynta Pharma, a company that develops anti-inflammatory drugs.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Copyright © 2020 Bergqvist, Sundström, Shang, Gunnarsson, Lundberg, Sundström, Jakobsson and Berg.** This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.